Poseida Therapeutics, Inc. (PSTX) Tops Q3 EPS by 63c
Tweet
Share
E-mailGet Alerts PSTX Hot Sheet
Price: $9.50 --0%
Financial Fact:
Research and development: 168.56K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development: 168.56K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q3 EPS of $0.21, $0.63 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $71.75 million versus the consensus estimate of $16.25 million.
For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS says bull market has further to run
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Needham Reiterates Buy Rating on Napco Security Technologies, Inc. (NSSC)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
